Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
General20 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Business18 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
Noosa News18 hours agoYIMBYs vs NIMBYs as the battle for affordable housing moves into your backyard
-
General17 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project